Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand
Background: In early 2021, the Ministry of Public Health of Thailand announced heterologous regimens for COVID-19 vaccines using CoronaVac as the first dose followed by ChAdOx1 nCoV-19 at 3 weeks apart. Priority was given to individuals above 60 years old and those who had seven underlying condition...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-06-01
|
| Series: | Vaccine: X |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590136224000482 |
| _version_ | 1797247685021925376 |
|---|---|
| author | Kriangkrai Chawansuntati Supachai Sakkhachornphop Sayamon Hongjaisee Saranta Freeouf Patumrat Sripan Nattaya Nusartsang Romanee Chaiwarith Tavitiya Sudjaritruk Khuanchai Supparatpinyo Jiraprapa Wipasa |
| author_facet | Kriangkrai Chawansuntati Supachai Sakkhachornphop Sayamon Hongjaisee Saranta Freeouf Patumrat Sripan Nattaya Nusartsang Romanee Chaiwarith Tavitiya Sudjaritruk Khuanchai Supparatpinyo Jiraprapa Wipasa |
| author_sort | Kriangkrai Chawansuntati |
| collection | DOAJ |
| description | Background: In early 2021, the Ministry of Public Health of Thailand announced heterologous regimens for COVID-19 vaccines using CoronaVac as the first dose followed by ChAdOx1 nCoV-19 at 3 weeks apart. Priority was given to individuals above 60 years old and those who had seven underlying conditions, including obesity. The vaccine regimen was evaluated for safety and immunogenicity in overweight populations in Chiang Mai, Thailand. Methods: Participants who had a COVID-19 vaccination appointment for the heterologous prime-boost regimen were enrolled. Before each immunization and on day 28 following the second dosage, blood samples were taken, and were examined for anti-spike and neutralizing antibodies by using an indirect ELISA and virus neutralization assays. Safety profile of the vaccine regimen was assessed via a self-recorded diary of adverse events after each vaccination. Results: No serious adverse events related to vaccination were reported during study period and the majority of adverse reactions were fatigue and pain at the injection site. The levels of anti-spike IgG were 26.3, 56.4 and 1752.1 BAU/mL at baseline, 21 days after first dose and 28 days after second dose, respectively. At 4 weeks after complete vaccination, the median inhibition rates of neutralizing antibody determined by surrogate neutralization assay against wild type, Delta and Omicron variants were 95.2, 85.0 and 3.8, respectively. Moreover, the NT50 level against wild type and Delta variants determined by pseudotyped virus neutralization assay were 133.3 and 41.7, respectively. The neutralizing activity against Omicron variant was almost lower than cutoff level for detection. Conclusions: The heterologous CoronaVac-ChAdOx1vaccination was safe, well-tolerated and able to induce humoral immunity against wild-type and Delta variants but not against the Omicron variant in overweight population. |
| first_indexed | 2024-04-24T20:02:37Z |
| format | Article |
| id | doaj.art-79d8e00a7362474cadfd31321a0356d9 |
| institution | Directory Open Access Journal |
| issn | 2590-1362 |
| language | English |
| last_indexed | 2024-04-24T20:02:37Z |
| publishDate | 2024-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Vaccine: X |
| spelling | doaj.art-79d8e00a7362474cadfd31321a0356d92024-03-24T07:01:30ZengElsevierVaccine: X2590-13622024-06-0118100475Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, ThailandKriangkrai Chawansuntati0Supachai Sakkhachornphop1Sayamon Hongjaisee2Saranta Freeouf3Patumrat Sripan4Nattaya Nusartsang5Romanee Chaiwarith6Tavitiya Sudjaritruk7Khuanchai Supparatpinyo8Jiraprapa Wipasa9Research Institute for Health Sciences, Chiang Mai University, Chiang Mai 50202, ThailandResearch Institute for Health Sciences, Chiang Mai University, Chiang Mai 50202, ThailandResearch Institute for Health Sciences, Chiang Mai University, Chiang Mai 50202, ThailandResearch Institute for Health Sciences, Chiang Mai University, Chiang Mai 50202, ThailandResearch Institute for Health Sciences, Chiang Mai University, Chiang Mai 50202, ThailandResearch Institute for Health Sciences, Chiang Mai University, Chiang Mai 50202, ThailandDivision of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50202, ThailandDivision of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50202, ThailandResearch Institute for Health Sciences, Chiang Mai University, Chiang Mai 50202, ThailandResearch Institute for Health Sciences, Chiang Mai University, Chiang Mai 50202, Thailand; Corresponding author at: Research Institute for Health Sciences, Chiang Mai University, 110 Intavaroros Road, Chiang Mai 50200, Thailand.Background: In early 2021, the Ministry of Public Health of Thailand announced heterologous regimens for COVID-19 vaccines using CoronaVac as the first dose followed by ChAdOx1 nCoV-19 at 3 weeks apart. Priority was given to individuals above 60 years old and those who had seven underlying conditions, including obesity. The vaccine regimen was evaluated for safety and immunogenicity in overweight populations in Chiang Mai, Thailand. Methods: Participants who had a COVID-19 vaccination appointment for the heterologous prime-boost regimen were enrolled. Before each immunization and on day 28 following the second dosage, blood samples were taken, and were examined for anti-spike and neutralizing antibodies by using an indirect ELISA and virus neutralization assays. Safety profile of the vaccine regimen was assessed via a self-recorded diary of adverse events after each vaccination. Results: No serious adverse events related to vaccination were reported during study period and the majority of adverse reactions were fatigue and pain at the injection site. The levels of anti-spike IgG were 26.3, 56.4 and 1752.1 BAU/mL at baseline, 21 days after first dose and 28 days after second dose, respectively. At 4 weeks after complete vaccination, the median inhibition rates of neutralizing antibody determined by surrogate neutralization assay against wild type, Delta and Omicron variants were 95.2, 85.0 and 3.8, respectively. Moreover, the NT50 level against wild type and Delta variants determined by pseudotyped virus neutralization assay were 133.3 and 41.7, respectively. The neutralizing activity against Omicron variant was almost lower than cutoff level for detection. Conclusions: The heterologous CoronaVac-ChAdOx1vaccination was safe, well-tolerated and able to induce humoral immunity against wild-type and Delta variants but not against the Omicron variant in overweight population.http://www.sciencedirect.com/science/article/pii/S2590136224000482Coronavirus disease (COVID-19)CoronaVacChAdOx1Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Neutralizing antibodies |
| spellingShingle | Kriangkrai Chawansuntati Supachai Sakkhachornphop Sayamon Hongjaisee Saranta Freeouf Patumrat Sripan Nattaya Nusartsang Romanee Chaiwarith Tavitiya Sudjaritruk Khuanchai Supparatpinyo Jiraprapa Wipasa Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand Vaccine: X Coronavirus disease (COVID-19) CoronaVac ChAdOx1 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing antibodies |
| title | Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand |
| title_full | Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand |
| title_fullStr | Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand |
| title_full_unstemmed | Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand |
| title_short | Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand |
| title_sort | safety and immunogenicity of coronavac and chadox1 heterologous prime boost vaccines in an overweight population in chiang mai thailand |
| topic | Coronavirus disease (COVID-19) CoronaVac ChAdOx1 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing antibodies |
| url | http://www.sciencedirect.com/science/article/pii/S2590136224000482 |
| work_keys_str_mv | AT kriangkraichawansuntati safetyandimmunogenicityofcoronavacandchadox1heterologousprimeboostvaccinesinanoverweightpopulationinchiangmaithailand AT supachaisakkhachornphop safetyandimmunogenicityofcoronavacandchadox1heterologousprimeboostvaccinesinanoverweightpopulationinchiangmaithailand AT sayamonhongjaisee safetyandimmunogenicityofcoronavacandchadox1heterologousprimeboostvaccinesinanoverweightpopulationinchiangmaithailand AT sarantafreeouf safetyandimmunogenicityofcoronavacandchadox1heterologousprimeboostvaccinesinanoverweightpopulationinchiangmaithailand AT patumratsripan safetyandimmunogenicityofcoronavacandchadox1heterologousprimeboostvaccinesinanoverweightpopulationinchiangmaithailand AT nattayanusartsang safetyandimmunogenicityofcoronavacandchadox1heterologousprimeboostvaccinesinanoverweightpopulationinchiangmaithailand AT romaneechaiwarith safetyandimmunogenicityofcoronavacandchadox1heterologousprimeboostvaccinesinanoverweightpopulationinchiangmaithailand AT tavitiyasudjaritruk safetyandimmunogenicityofcoronavacandchadox1heterologousprimeboostvaccinesinanoverweightpopulationinchiangmaithailand AT khuanchaisupparatpinyo safetyandimmunogenicityofcoronavacandchadox1heterologousprimeboostvaccinesinanoverweightpopulationinchiangmaithailand AT jiraprapawipasa safetyandimmunogenicityofcoronavacandchadox1heterologousprimeboostvaccinesinanoverweightpopulationinchiangmaithailand |